Search
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.
Zaleplon
go.drugbank.com/drugs/DB00962ApprovedIllicitZaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Categories: GABA-A Receptor Agonists, gamma-Aminobutyric Acid A Receptor AgonistKeyhole limpet hemocyanin
go.drugbank.com/drugs/DB05299ApprovedInvestigationalWithdrawnKeyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. … Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins.
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnIt binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. … in the US.
Basiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalA recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … known as CD25 antigen) on the surface of activated T-lymphocytes.
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking AntibodyProducts: SIMULECT 20 MG İNFÜZYON VEYA ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[A232558] The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. … [A232608] Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and [brexucabtagene autoleucel].
Synonyms: Anti-BCMA CAR T cellCategories: Receptors, Antigen, T-CellN-Acetylglucosamine
go.drugbank.com/drugs/DB00141ApprovedInvestigationalNutraceuticalThe N-acetyl derivative of glucosamine.
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalBoth T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers. … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).
Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB16901ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16904ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.